GlassScriptPhysician profile
Fatima Saifuddin
NPI 1093196230
$1,479.42
in general payments reported to CMS, 2019-2025
20 companies · $770 in 2025
The $770 reported for 2025 was more than what 81% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $286 · 2020: $59.95 · 2023: $41.69 · 2024: $322 · 2025: $770.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,134.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,133.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $190.29 | 2019-2025 | |
| Novo Nordisk INC | $171.58 | 2019-2025 | Ozempic, Rybelsus |
| Glaxosmithkline, LLC. | $156.57 | 2019-2025 | Bexsero, Arexvy, Shingrix |
| Amgen INC. | $143.37 | 2019-2025 | Evenity, Repatha, Otezla |
| Lilly USA, LLC | $124.42 | 2020-2025 | Mounjaro, Zepbound |
| Astellas Pharma US INC | $119.99 | 2019-2025 | Veozah |
| Otsuka America Pharmaceutical, INC. | $114.31 | 2025 | Rexulti |
| Exact Sciences Corporation | $61.16 | 2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $56.86 | 2019-2024 | Jardiance, Tradjenta |
| Astrazeneca Pharmaceuticals LP | $54.62 | 2019-2024 | Farxiga |
| Xeris Pharmaceuticals, INC. | $46.48 | 2024 | Gvoke Hypopen |
| Medtronic, INC. | $45.13 | 2024 | Pteye Parathyroid Detection System |
| Shield Therapeutics INC | $34.50 | 2025 | |
| Gilead Sciences, INC. | $28.01 | 2019 | |
| Axsome Therapeutics, INC. | $27.43 | 2025 | Symbravo |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Smith+Nephew, INC. | $24.49 | 2023 | Versajet, Collagenase Santyl, Oasis |
| Phathom Pharmaceuticals, INC. | $24.04 | 2024 | Voquezna |
| Dexcom, INC. | $22.95 | 2024 | Dexcom G6 Transmitter |
| Abbott Laboratories | $17.20 | 2023 | Freestyle Libre 2 |
| Sanofi-Aventis U.S. LLC | $16.02 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Fatima Saifuddin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.